NHL27

Australasian Leukaemia and Lymphoma Group (ALLG)

Pauline Warburton (Wollongong Hospital)

This dataset contains individual participant data (IPD) from the NHL27 study, a phase 3 open-label randomised trial comparing the efficacy and safety of rituximab plus lenalidomide versus rituximab plus chemotherapy followed by rituximab maintenance in patients with previously untreated follicular lymphoma.

The dataset includes patient-level demographic and clinical information such as age, sex, disease stage, prognostic risk factors, and baseline laboratory values. Treatment data include allocated therapy, dosing, treatment duration, and exposure. Outcome data include response assessments, progression-free survival, overall survival, and adverse events.

The study population comprises approximately 750 (globally) adult patients with previously untreated follicular lymphoma enrolled across Australasian sites. Data are collected at predefined timepoints including baseline, during induction therapy, during maintenance treatment, and at scheduled follow-up visits for disease assessment and survival outcomes.

This dataset is suitable for secondary analyses including comparative effectiveness research, evaluation of treatment response and durability, safety profiling, and optimisation of first-line treatment strategies in follicular lymphoma.

Australasian Leukaemia and Lymphoma Group (ALLG)

Oncology and Carcinogenesis

• Metabolic tumor volume predicts outcome in patients with advanced stage follicular lymphoma from the RELEVANCE trial
• Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.

Access can be requested via the Health Data Australia catalogue. Search for the ACTRN number in the catalogue to find datasets associated with this trial or email enquiries to info@allg.org.au